RaQualia Pharma Inc. (4579.T)
JPY 377.0
(-1.31%)
JPY 377.0
(-1.31%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 147.93 Million JPY | 1640.46% |
| 2022 | 8.5 Million JPY | -19.41% |
| 2021 | 10.54 Million JPY | 61.27% |
| 2020 | 6.54 Million JPY | 18.91% |
| 2019 | 5.5 Million JPY | -15.36% |
| 2018 | 6.49 Million JPY | 26.1% |
| 2017 | 5.15 Million JPY | -27.68% |
| 2016 | 7.12 Million JPY | -0.32% |
| 2015 | 7.14 Million JPY | -18.1% |
| 2014 | 8.72 Million JPY | -81.5% |
| 2013 | 47.19 Million JPY | -1.18% |
| 2012 | 47.75 Million JPY | 5.86% |
| 2011 | 45.11 Million JPY | -11.26% |
| 2010 | 50.83 Million JPY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 169.51 Million JPY | 14.59% |
| 2024 Q2 | 174.88 Million JPY | 3.17% |
| 2023 Q2 | 8.36 Million JPY | -2.36% |
| 2023 FY | 147.93 Million JPY | 1640.46% |
| 2023 Q4 | 147.93 Million JPY | 1807.66% |
| 2023 Q3 | 7.75 Million JPY | -7.31% |
| 2023 Q1 | 8.56 Million JPY | 0.81% |
| 2022 Q1 | 9.57 Million JPY | -9.19% |
| 2022 Q2 | 8.35 Million JPY | -12.81% |
| 2022 Q4 | 8.5 Million JPY | -7.38% |
| 2022 FY | 8.5 Million JPY | -19.41% |
| 2022 Q3 | 9.17 Million JPY | 9.89% |
| 2021 FY | 10.54 Million JPY | 61.27% |
| 2021 Q1 | 15.95 Million JPY | 143.96% |
| 2021 Q2 | 14.82 Million JPY | -7.08% |
| 2021 Q3 | 11.86 Million JPY | -19.96% |
| 2021 Q4 | 10.54 Million JPY | -11.12% |
| 2020 Q4 | 6.54 Million JPY | 44.05% |
| 2020 Q2 | 4.96 Million JPY | -3.08% |
| 2020 FY | 6.54 Million JPY | 18.91% |
| 2020 Q1 | 5.12 Million JPY | -6.87% |
| 2020 Q3 | 4.54 Million JPY | -8.54% |
| 2019 Q1 | 6.26 Million JPY | -3.55% |
| 2019 Q2 | 5.78 Million JPY | -7.77% |
| 2019 Q3 | 16.02 Million JPY | 177.28% |
| 2019 Q4 | 5.5 Million JPY | -65.68% |
| 2019 FY | 5.5 Million JPY | -15.36% |
| 2018 Q3 | 5.52 Million JPY | 17.66% |
| 2018 Q2 | 4.69 Million JPY | -3.47% |
| 2018 Q4 | 6.49 Million JPY | 17.53% |
| 2018 FY | 6.49 Million JPY | 26.1% |
| 2018 Q1 | 4.86 Million JPY | -5.53% |
| 2017 Q2 | 8.71 Million JPY | 25.33% |
| 2017 FY | 5.15 Million JPY | -27.68% |
| 2017 Q4 | 5.15 Million JPY | 12.88% |
| 2017 Q3 | 4.56 Million JPY | -47.64% |
| 2017 Q1 | 6.95 Million JPY | -2.36% |
| 2016 FY | 7.12 Million JPY | -0.32% |
| 2016 Q1 | 5.06 Million JPY | -29.1% |
| 2016 Q2 | 8.12 Million JPY | 60.24% |
| 2016 Q3 | 5.93 Million JPY | -26.87% |
| 2016 Q4 | 7.12 Million JPY | 19.97% |
| 2015 FY | 7.14 Million JPY | -18.1% |
| 2015 Q1 | 8.02 Million JPY | -8.11% |
| 2015 Q2 | 7.9 Million JPY | -1.5% |
| 2015 Q4 | 7.14 Million JPY | 13137.04% |
| 2015 Q3 | 54 Thousand JPY | -99.32% |
| 2014 FY | 8.72 Million JPY | -81.5% |
| 2014 Q3 | 32.34 Million JPY | -3.06% |
| 2014 Q4 | 8.72 Million JPY | -73.02% |
| 2014 Q2 | 33.36 Million JPY | -12.38% |
| 2014 Q1 | 38.08 Million JPY | -19.3% |
| 2013 Q3 | 48.79 Million JPY | -2.11% |
| 2013 Q1 | 52.3 Million JPY | 9.52% |
| 2013 FY | 47.19 Million JPY | -1.18% |
| 2013 Q2 | 49.85 Million JPY | -4.68% |
| 2013 Q4 | 47.19 Million JPY | -3.3% |
| 2012 Q4 | 47.75 Million JPY | -1.16% |
| 2012 Q1 | 48.76 Million JPY | 8.1% |
| 2012 Q3 | 48.31 Million JPY | 9.7% |
| 2012 Q2 | 44.04 Million JPY | -9.68% |
| 2012 FY | 47.75 Million JPY | 5.86% |
| 2011 Q4 | 45.11 Million JPY | -18.14% |
| 2011 Q3 | 55.1 Million JPY | 15.69% |
| 2011 Q2 | 47.63 Million JPY | 0.0% |
| 2011 FY | 45.11 Million JPY | -11.26% |
| 2010 FY | 50.83 Million JPY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 683.01 Million JPY | 78.34% |
| PRISM BioLab Co.,LTD | 17.92 Million JPY | -725.138% |
| GNI Group Ltd. | 2.33 Billion JPY | 93.652% |
| Linical Co., Ltd. | - JPY | -Infinity% |
| Trans Genic Inc. | 2.22 Billion JPY | 93.359% |
| MEDINET Co., Ltd. | 67.48 Million JPY | -119.231% |
| Soiken Holdings Inc. | 1.12 Billion JPY | 86.801% |
| Cytori Cell Research Institute, Inc. | 103.53 Million JPY | -42.889% |
| AnGes, Inc. | 1.61 Billion JPY | 90.844% |
| OncoTherapy Science, Inc. | 73.99 Million JPY | -99.92% |
| Nxera Pharma Co., Ltd. | 2.9 Billion JPY | 94.904% |
| Immuno-Biological Laboratories Co., Ltd. | 321.91 Million JPY | 54.044% |
| NanoCarrier Co., Ltd. | 184 Thousand JPY | -80301.63% |
| Carna Biosciences, Inc. | 140.14 Million JPY | -5.565% |
| CanBas Co., Ltd. | 728 Thousand JPY | -20221.291% |
| D. Western Therapeutics Institute, Inc. | 87.86 Million JPY | -68.375% |
| Chiome Bioscience Inc. | 64.1 Million JPY | -130.769% |
| Kidswell Bio Corporation | 875.65 Million JPY | 83.105% |
| PeptiDream Inc. | 2.4 Billion JPY | 93.847% |
| Oncolys BioPharma Inc. | 5.34 Million JPY | -2669.356% |
| Ribomic Inc. | 2.27 Million JPY | -6405.673% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | - JPY | -Infinity% |
| BrightPath Biotherapeutics Co., Ltd. | 1.00 JPY | -14793899900.0% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 36 Million JPY | -310.942% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | 29 Million JPY | -410.134% |
| CellSource Co., Ltd. | 305.92 Million JPY | 51.642% |
| FunPep Company Limited | 25.54 Million JPY | -479.222% |
| Kringle Pharma, Inc. | 364.05 Million JPY | 59.364% |
| Stella Pharma Corporation | 1.11 Billion JPY | 86.747% |
| TMS Co., Ltd. | 50.02 Million JPY | -195.73% |
| Noile-Immune Biotech Inc. | 20.9 Million JPY | -607.808% |
| Cuorips Inc. | 1.04 Million JPY | -14083.988% |
| K Pharma,Inc. | 10.79 Million JPY | -1270.567% |
| Takara Bio Inc. | 11.85 Billion JPY | 98.752% |
| ReproCELL Incorporated | 248.14 Million JPY | 40.381% |
| PhoenixBio Co., Ltd. | 450.58 Million JPY | 67.167% |
| StemCell Institute Inc. | 42.26 Million JPY | -250.052% |
| Japan Tissue Engineering Co., Ltd. | 228.56 Million JPY | 35.275% |
| CellSeed Inc. | 46.19 Million JPY | -220.277% |